Farnesyl pyrophosphate



Compound IDCDAMM00503
Common nameFarnesyl pyrophosphate
IUPAC namephosphono 3,7,11-trimethyldodeca-2,6,10-trienyl hydrogen phosphate
Molecular formulaC15H28O7P2

Experimental data

Retention time10.33
Adduct[M+H]+
Actual mz383.14
Theoretical mz383.138
Error5.02
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score7.2589

Identifiers and class information

Inchi keyVWFJDQUYCIWHTN-YFVJMOTDSA-N
SmilesO=P(O)(O)OP(=O)(O)OCC=C(C)CCC=C(C)CCC=C(C)C
SuperclassLipids and lipid-like molecules
ClassPrenol lipids

Pharmacokinetic properties

Number of descriptor values(#stars)1
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)3
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)14
Number of reactive functional groups (#rtvFG)2
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)382.33
Computed dipole moment(dipole)7.644
Total solvent accessible surface area (SASA)722.234
Hydrophobic component of SASA (FOSA)458.428
Hydrophilic component of SASA (FISA)231.702
Pie component of the SASA (PISA)24.526
Weakly polar component of the SASA (WPSA)7.579
Total solvent accesible volume (volume)1259.57
Number of hydrogen bond donors (donorHB)0
Number of hydrogen bond acceptors (accptHB)7
Free energy of solvation of dipole (dip^2/V)0.0463943
Index of cohesive interaction in solids (ACxDN^.5/SA)0
Globularity descriptor (glob)0.780973
Predicted polarizability in cubic angstroms (QPpolrz)35.499
Predicted hexadecane/gas partition coefficient (QPlogPC16)11.872
Predicted octanol/gas partition coefficient (QPlogPoct)15.723
Predicted water/gas partition coefficient (QPlogPw)7.009
Predicted octanol/water partition coefficient (QPlogPo/w)4.105
Predicted aqueous solubility (QPlogS)-3.992
Conformation-independent predicted aqueous solubility (CIQPlogS)-3.945
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)0.229
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)1.022
Predicted brain/blood partition coefficient (QPlogBB)-2.794
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.656
Predicted skin permeability, log Kp (QPlogKp)-4.359
PM3 calculated ionization potential (IP(ev))9.168
PM3 calculated electron affinity (EA(eV))0.045
Number of likely metabolic reactions (#metab)9
Prediction of binding to human serum albumin (QPlogKhsa)-0.676
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)51.148
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)122.493
Number of nitrogen and oxygen atoms (#NandO)7
Number of violations of Lipinski’s rule of five (RuleOfFive)0
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P48449LSSLanosterol synthaseT56175SEA
P15121AKR1B1Aldose reductaseT26623SwissTargetPrediction
O14842FFAR1Free fatty acid receptor 1T25608SwissTargetPrediction
Q14534SQLESqualene monooxygenase (by homology)T93344SEA
Q16539MAPK14MAP kinase p38 alphaT65864SwissTargetPrediction
P49356FNTBFarnesyl protein transferaseT13127SwissTargetPrediction and SEA
P41279MAP3K8Mitogen-activated protein kinase kinase kinase 8T00852SwissTargetPrediction
P25025CXCR2Interleukin-8 receptor BT56923SwissTargetPrediction
P53609PGGT1BGeranylgeranyl transferase type IT76396SwissTargetPrediction and SEA
Q13526PIN1Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1T16308SwissTargetPrediction
P49356FNTBFarnesyl protein transferaseT13127SEA
O95749GGPS1GeranyltranstransferaseT86528SEA
P53602MVDDiphosphomevalonate decarboxylaseT96862SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T56175DI0035Arterial occlusive disease[ICD-11: BD40]P48449LSS
T26623DI0298Neuropathy[ICD-11: 8C0Z]P15121AKR1B1
T26623DI0366Rheumatoid arthritis[ICD-11: FA20]P15121AKR1B1
T25608DI0417Type 2 diabetes mellitus[ICD-11: 5A11]O14842FFAR1
T93344DI0118Dermatophytosis[ICD-11: 1F28]Q14534SQLE
T93344DI0385Skin fungal infection disorder[ICD-11: EA60]Q14534SQLE
T65864DI0102Coronary atherosclerosis[ICD-11: BA52]Q16539MAPK14
T65864DI0287Myocardial infarction[ICD-11: BA41-BA43]Q16539MAPK14
T65864DI0366Rheumatoid arthritis[ICD-11: FA20]Q16539MAPK14
T65864DI0437Vitamin deficiency[ICD-11: 5B55-5B5F]Q16539MAPK14
T13127DI0342Premature ageing appearance[ICD-11: LD2B]P49356FNTB
T00852DI0207Indeterminate colitis[ICD-11: DD72]P41279MAP3K8
T56923DI0155Fungal infection[ICD-11: 1F29-1F2F]P25025CXCR2
T56923DI0324Pain[ICD-11: MG30-MG3Z]P25025CXCR2
T76396DI0241Lymphoma[ICD-11: 2A80-2A86]P53609PGGT1B
T16308DI0238Lung cancer[ICD-11: 2C25]Q13526PIN1
T13127DI0342Premature ageing appearance[ICD-11: LD2B]P49356FNTB
T86528DI0057Bone paget disease[ICD-11: FB85]O95749GGPS1
T86528DI0237Low bone mass disorder[ICD-11: FB83]O95749GGPS1
T86528DI0267Mineral excesses[ICD-11: 5B91]O95749GGPS1
T86528DI0281Musculoskeletal disorder[ICD-11: FA00-FC0Z]O95749GGPS1

Copyright © 2025